Coherus Pulls A Rabbit Out Of The Hat With Inventive Pegfilgrastim Form
Firm Guiding For Q2 Launch, On-Body Injector Set To Follow Later In 2023
Coherus’ year-end financial results included a surprise – a newly approved formulation of pegfilgrastim.
You may also be interested in...
Coherus BioSciences has swiftly returned a filing for its on-body pegfilgrastim biosimilar candidate to the US Food and Drug Administration, while hitting a milestone for its Cimerli biosimilar to Lucentis (ranibizumab).
Coherus BioSciences says that it will work closely with the US Food and Drug Administration and the unnamed third-party filler to obtain approval for its proposed version of Neulasta Onpro on-body injector “as quickly as possible.”
In the third part of this year’s Generics Bulletin Top 50, we look at how various increases and declines for companies at the bottom of our table have affected their positions in the ranking.